<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Candida glabrata - UTI PathoDB</title>
    <link href="https://cdn.jsdelivr.net/npm/tailwindcss@2.2.19/dist/tailwind.min.css" rel="stylesheet">
</head>
<body class="bg-gray-50 text-gray-900">

    <header class="bg-purple-600 text-white p-4 shadow-md">
        <h1 class="text-2xl font-bold text-center">Candida glabrata - UTI PathoDB</h1>
    </header>

    <main class="p-6 space-y-6 max-w-4xl mx-auto">

        <!-- Overview -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Overview</h2>
            <p>
                <strong>Candida glabrata</strong> is a yeast species that is part of the normal human microbiota but can cause opportunistic infections, including urinary tract infections (UTIs). It is especially significant in elderly and immunocompromised individuals.
            </p>
        </section>

        <!-- Characteristics -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Characteristics</h2>
            <ul class="list-disc list-inside space-y-1">
                <li>Unicellular yeast</li>
                <li>Non-dimorphic (does not form true hyphae)</li>
                <li>Part of normal flora of the gastrointestinal and genitourinary tracts</li>
                <li>Inherently less susceptible to azole antifungals</li>
            </ul>
        </section>

        <!-- Pathogenicity -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Pathogenicity</h2>
            <p>
                Candida glabrata can cause UTIs, particularly in patients using urinary catheters, diabetic patients, and those receiving immunosuppressive therapy. Its ability to adhere to uroepithelial cells and form biofilms contributes to its pathogenicity.
            </p>
        </section>

        <!-- Clinical Significance -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Clinical Significance</h2>
            <p>
                C. glabrata is associated with funguria and invasive candidiasis. It demonstrates higher resistance to azole antifungals compared to other Candida species, necessitating careful antifungal selection based on susceptibility testing.
            </p>
        </section>

        <!-- Treatment -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Treatment</h2>
            <p>
                Treatment includes the use of echinocandins or amphotericin B, especially in resistant cases. Fluconazole may be less effective due to intrinsic resistance. Removal of indwelling catheters is often necessary in UTI management.
            </p>
        </section>

        <!-- References -->
        <section>
            <h2 class="text-xl font-semibold mb-2">References</h2>
            <ul class="list-decimal list-inside space-y-1">
                <li>Pfaller MA, Diekema DJ. "Epidemiology of invasive candidiasis: A persistent public health problem." Clin Microbiol Rev. 2007.</li>
                <li>Pappas PG, et al. "Clinical practice guidelines for the management of candidiasis." Clin Infect Dis. 2016.</li>
            </ul>
        </section>

        <!-- Back to Home Link -->
        <div class="mt-6">
            <a href="index.html" class="text-purple-600 hover:underline">&larr; Back to Home</a>
        </div>

    </main>

    <footer class="bg-gray-200 text-center p-4 mt-6">
        &copy; 2025 UTI PathoDB. All rights reserved.
    </footer>

</body>
</html>
